Received Apr 8, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 3 | 7349L | — |
a third dose of Shingrix was inadvertently administered to a patient; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of extra dose administered in a 56-year-old male patient who received Herpes zoster (Shingrix) (batch number 7349L, expiry date 25-MAR-2027) for prophylaxis. Previously administered products included Shingrix (First dose of Shingrix was given on 21st June 2023) and Shingrix (Second dose of Shingrix was given on 30th August 2023). On 03-APR-2025, the patient received the 3rd dose of Shingrix. On 03-APR-2025, an unknown time after receiving Shingrix, the patient experienced extra dose administered (Verbatim: a third dose of Shingrix was inadvertently administered to a patient). The outcome of the extra dose administered was not applicable. Additional Information: GSK Receipt Date : 03-APR-2025 Pharmacist called to report a third dose of Shingrix was inadvertently administered to a patient which led to extra dose administered. The vaccine administration facility was the same as primary reporter.